VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+12.8%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$237M
AUM Growth
+$237M
(-1.7%)
Cap. Flow
-$15.8M
Cap. Flow
% of AUM
-6.68%
Top 10 Holdings %
Top 10 Hldgs %
7.93%
Holding
416
New
61
Increased
247
Reduced
47
Closed
61
Top Buys
| 1 |
EOG Resources
EOG
|
$2.02M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.99M |
| 3 |
ConocoPhillips
COP
|
$1.85M |
| 4 |
Imperial Oil
IMO
|
$1.8M |
| 5 |
Reliance Steel & Aluminium
RS
|
$1.76M |
Top Sells
| 1 |
Ryman Hospitality Properties
RHP
|
$2.57M |
| 2 |
Western Midstream Partners
WES
|
$2.52M |
| 3 |
INN
Summit Hotel Properties
INN
|
$2.43M |
| 4 |
Brookfield Renewable
BEPC
|
$2.38M |
| 5 |
Grupo Aeroportuario del Pacifico
PAC
|
$2.16M |
Sector Composition
| 1 | Healthcare | 30.46% |
| 2 | Real Estate | 18.03% |
| 3 | Energy | 13.68% |
| 4 | Materials | 11.34% |
| 5 | Utilities | 10.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Omeros
OMER
$292M
| $733K | 0.31% |
41,200
+1,132
| +3% | +$20.1K |
|
102
United Therapeutics
UTHR
$18.3B
| $732K | 0.31% |
4,376
+124
| +3% | +$20.7K |
|
103
Enanta Pharmaceuticals
ENTA
$192M
| $726K | 0.31% |
14,721
+400
| +3% | +$19.7K |
|
104
Vanda Pharmaceuticals
VNDA
$278M
| $720K | 0.3% |
47,914
+1,312
| +3% | +$19.7K |
|
105
Biogen
BIIB
$20.5B
| $713K | 0.3% |
2,550
+68
| +3% | +$19K |
|
106
Nektar Therapeutics
NKTR
$553M
| $710K | 0.3% |
35,476
+973
| +3% | +$19.5K |
|
107
Nuveen Credit Strategies Income Fund
JQC
$759M
| $698K | 0.29% |
107,355
+18,827
| +21% | +$122K |
|
108
Exelixis
EXEL
$10B
| $687K | 0.29% |
30,432
+830
| +3% | +$18.7K |
|
109
Amgen
AMGN
$154B
| $684K | 0.29% |
2,750
+98
| +4% | +$24.4K |
|
110
Gilead Sciences
GILD
$140B
| $684K | 0.29% |
10,578
+407
| +4% | +$26.3K |
|
111
Carlyle Secured Lending
CGBD
$1.01B
| $681K | 0.29% |
51,567
-1,208
| -2% | -$16K |
|
112
Theravance Biopharma
TBPH
$697M
| $671K | 0.28% |
32,871
+905
| +3% | +$18.5K |
|
113
Alnylam Pharmaceuticals
ALNY
$58.6B
| $667K | 0.28% |
4,721
+134
| +3% | +$18.9K |
|
|
SAGE
114
DELISTED
Sage Therapeutics
SAGE
| $663K | 0.28% |
8,852
+241
| +3% | +$18.1K |
|
|
XLRN
115
DELISTED
Acceleron Pharma Inc.
XLRN
| $652K | 0.28% |
4,810
+129
| +3% | +$17.5K |
|
116
Neurocrine Biosciences
NBIX
$14.1B
| $651K | 0.28% |
6,692
+180
| +3% | +$17.5K |
|
|
FPRX
117
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $645K | 0.27% |
17,112
+302
| +2% | +$11.4K |
|
118
BioNTech
BNTX
$24.2B
| $631K | 0.27% |
5,779
+158
| +3% | +$17.3K |
|
119
Halozyme
HALO
$8.58B
| $623K | 0.26% |
14,954
+411
| +3% | +$17.1K |
|
120
ImmunityBio
IBRX
$2.25B
| $614K | 0.26% |
25,850
+462
| +2% | +$11K |
|
|
ALXN
121
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $613K | 0.26% |
4,009
+115
| +3% | +$17.6K |
|
122
Barings BDC
BBDC
$1.03B
| $606K | 0.26% |
60,759
-19,706
| -24% | -$197K |
|
123
Travere Therapeutics
TVTX
$1.62B
| $597K | 0.25% |
+23,907
| New | +$597K |
|
|
GBT
124
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $597K | 0.25% |
14,654
+400
| +3% | +$16.3K |
|
125
Esperion Therapeutics
ESPR
$468M
| $593K | 0.25% |
21,157
+581
| +3% | +$16.3K |
|